BPC-157
Body Protection Compound-157 | Pentadecapeptide
BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a protective protein found in human gastric juice. It's known for its remarkable healing properties and is extensively researched for tissue repair, inflammation reduction, and gastrointestinal protection. Not FDA approved and prohibited by WADA (added 2022) under S0: Non-Approved Substances - no TUE available for athletes.
Daily dose
250-500mcg
Frequency
1-2x
Cycle length
4-8 weeks
Storage
2-6°C
Key benefits
Accelerated healing of tendons, ligaments, muscles, bones, and gastric tissue. Anti-inflammatory effects without immune suppression.
How it works
BPC-157 promotes angiogenesis (formation of new blood vessels), enhances collagen synthesis, modulates growth factor expression, and protects against various toxins and injuries. It's remarkably stable in gastric acid and demonstrates high bioavailability both orally and via injection.
Dosage protocols
Goal
General healing
Dose
250-500mcg · 1-2x daily
Route
SubQ or IM
Goal
Serious injury
Dose
500-1000mcg · 2x daily
Route
SubQ near injury
Goal
Gastric issues
Dose
500mcg-1mg · 1-2x daily
Route
Oral (empty stomach)
Goal
Maintenance
Dose
250mcg · 1x daily
Route
SubQ
Research indications
gastrointestinal
wound Healing
neurological
Administration
Interactions
Safety notes
May lower blood pressure slightly
Consult doctor if on blood thinners due to angiogenesis effects
Not recommended during pregnancy or breastfeeding
WADA prohibited (S0: Non-Approved Substances) - not for competitive athletes
Research studies
Gastric Ulcer Protection (2020)
Rats | Multiple routes tested | Various durations | Cytoprotective effects
Comprehensive study showing BPC-157's protective effects against gastric ulcers through multiple mechanisms including cytoprotection and enhanced mucosal healing.
View study →Safety Evaluation Study (2020)
Multiple species | Up to 1000 μg/kg | 90 days | Comprehensive toxicology
Preclinical safety evaluation showing no serious adverse effects at therapeutic doses, establishing safety profile for potential clinical applications.
View study →Spinal Cord Injury Recovery (2019)
Rats | 10 μg/kg i.p. daily | 30 days | Improved functional recovery
BPC-157 treatment resulted in significant functional recovery, reduced tissue damage, and improved neurological outcomes in spinal cord injury models.
View study →VEGF and Angiogenesis Study (2017)
In vitro and in vivo | Various concentrations | VEGFR2 activation measured
Demonstrated BPC-157's pro-angiogenic effects through VEGFR2 activation and upregulation, explaining its wound healing and tissue repair mechanisms.
View study →Muscle Healing Research (2006)
Rats | 10 μg/kg i.p. daily | 28 days | Enhanced muscle regeneration
Accelerated healing of transected quadriceps muscle with improved histological appearance, reduced inflammatory markers, and restored muscle function compared to control groups.
View study →Achilles Tendon Healing Study (2003)
Rats | 10 μg/kg i.p. daily | 14 days | Significant improvement in tendon healing
BPC-157 demonstrated superior healing of transected Achilles tendons compared to controls, with improved biomechanical properties, faster functional recovery, and enhanced tendon-to-bone integration.
View study →